drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00637 | DB00845 | 1,557 | 1,490 | [
"DDInter128",
"DDInter406"
] | Astemizole | Clofazimine | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloratio... | Moderate | 1 | [
[
[
1557,
24,
1490
]
],
[
[
1557,
6,
4973
],
[
4973,
45,
1490
]
],
[
[
1557,
23,
112
],
[
112,
62,
1490
]
],
[
[
1557,
24,
1250
],
[
1250,... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofazimine"
]
],
[
[
"Astemizole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Astemizole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clofazimine (Compound)
Astemizole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Clofazimine
Astemizole may c... |
DB00443 | DB05679 | 251 | 1,683 | [
"DDInter195",
"DDInter1907"
] | Betamethasone | Ustekinumab | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
251,
24,
1683
]
],
[
[
251,
62,
1461
],
[
1461,
23,
1683
]
],
[
[
251,
23,
1193
],
[
1193,
62,
1683
]
],
[
[
251,
24,
1129
],
[
1129,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Betamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
... | Betamethasone may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Betamethasone may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zin... |
DB00031 | DB01197 | 20 | 1,603 | [
"DDInter1764",
"DDInter292"
] | Tenecteplase | Captopril | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment ... | Moderate | 1 | [
[
[
20,
24,
1603
]
],
[
[
20,
24,
610
],
[
610,
1,
1603
]
],
[
[
20,
24,
1061
],
[
1061,
24,
1603
]
],
[
[
20,
25,
802
],
[
802,
63,... | [
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
],
[
... | Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril (Compound) resembles Captopril (Compound)
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that ... |
DB01005 | DB06688 | 995 | 1,430 | [
"DDInter894",
"DDInter1677"
] | Hydroxyurea | Sipuleucel-T | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
995,
24,
1430
]
],
[
[
995,
63,
51
],
[
51,
24,
1430
]
],
[
[
995,
24,
869
],
[
869,
24,
1430
]
],
[
[
995,
25,
676
],
[
676,
63... | [
[
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
],
... | Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and... |
DB00067 | DB11730 | 317 | 351 | [
"DDInter1921",
"DDInter1588"
] | Vasopressin | Ribociclib | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
317,
25,
351
]
],
[
[
317,
23,
112
],
[
112,
23,
351
]
],
[
[
317,
24,
1532
],
[
1532,
24,
351
]
],
[
[
317,
24,
129
],
[
129,
2... | [
[
[
"Vasopressin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Vasopressin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and If... |
DB01142 | DB01202 | 1,264 | 1,435 | [
"DDInter593",
"DDInter1046"
] | Doxepin | Levetiracetam | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).[L8606,L8600,L8615] Levetiracetam poss... | Moderate | 1 | [
[
[
1264,
24,
1435
]
],
[
[
1264,
6,
4973
],
[
4973,
45,
1435
]
],
[
[
1264,
21,
28769
],
[
28769,
60,
1435
]
],
[
[
1264,
63,
701
],
[
70... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levetiracetam"
]
],
[
[
"Doxepin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Doxepin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Levetiracetam (Compound)
Doxepin (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Levetiracetam (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Clemastine... |
DB00099 | DB01229 | 440 | 973 | [
"DDInter735",
"DDInter1377"
] | Filgrastim | Paclitaxel | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Moderate | 1 | [
[
[
440,
24,
973
]
],
[
[
440,
24,
310
],
[
310,
63,
973
]
],
[
[
440,
24,
134
],
[
134,
24,
973
]
],
[
[
440,
63,
491
],
[
491,
24,... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vin... |
DB01005 | DB08904 | 995 | 375 | [
"DDInter894",
"DDInter342"
] | Hydroxyurea | Certolizumab pegol | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
995,
25,
375
]
],
[
[
995,
63,
1461
],
[
1461,
23,
375
]
],
[
[
995,
24,
200
],
[
200,
63,
375
]
],
[
[
995,
63,
66
],
[
66,
24,... | [
[
[
"Hydroxyurea",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"V... | Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Candida albican... |
DB00252 | DB00792 | 362 | 832 | [
"DDInter1460",
"DDInter1878"
] | Phenytoin | Tripelennamine | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
362,
24,
832
]
],
[
[
362,
24,
100
],
[
100,
63,
832
]
],
[
[
362,
1,
939
],
[
939,
1,
832
]
],
[
[
362,
24,
649
],
[
649,
1,
... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
... | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Phenytoin (Compound) resembles Benzphetamine (Compound) and Benzphetamine (Compound) resembles Trip... |
DB01001 | DB01136 | 688 | 772 | [
"DDInter1632",
"DDInter305"
] | Salbutamol | Carvedilol | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Major | 2 | [
[
[
688,
25,
772
]
],
[
[
688,
24,
371
],
[
371,
1,
772
]
],
[
[
688,
6,
8374
],
[
8374,
45,
772
]
],
[
[
688,
21,
28734
],
[
28734,
... | [
[
[
"Salbutamol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carvedilol"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propafenone"
],
[
"Propafeno... | Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Propafenone and Propafenone (Compound) resembles Carvedilol (Compound)
Salbutamol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Carvedilol (Compound)
Salbutamol (Compound) causes Immune system disorder (Side Effect... |
DB00075 | DB08880 | 541 | 1,510 | [
"DDInter1250",
"DDInter1771"
] | Muromonab | Teriflunomide | Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
541,
25,
1510
]
],
[
[
541,
23,
1461
],
[
1461,
23,
1510
]
],
[
[
541,
23,
1193
],
[
1193,
62,
1510
]
],
[
[
541,
24,
221
],
[
221,
... | [
[
[
"Muromonab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Muromonab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
... | Muromonab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Muromonab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluc... |
DB00214 | DB00486 | 1,028 | 1,614 | [
"DDInter1836",
"DDInter1253"
] | Torasemide | Nabilone | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Moderate | 1 | [
[
[
1028,
24,
1614
]
],
[
[
1028,
24,
530
],
[
530,
1,
1614
]
],
[
[
1028,
21,
28789
],
[
28789,
60,
1614
]
],
[
[
1028,
24,
999
],
[
999,... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
... | Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol (Compound) resembles Nabilone (Compound)
Torasemide (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Nabilone (Compound)
Torasemide may cause a m... |
DB00005 | DB12498 | 1,057 | 76 | [
"DDInter687",
"DDInter1238"
] | Etanercept | Mogamulizumab | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become canc... | Major | 2 | [
[
[
1057,
25,
76
]
],
[
[
1057,
23,
1461
],
[
1461,
23,
76
]
],
[
[
1057,
25,
1531
],
[
1531,
24,
76
]
],
[
[
1057,
24,
496
],
[
496,
... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Etanercept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E"... | Etanercept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Mogamulizumab
Etanercept may lead to a major life threatening interaction when taken with Canakinumab and Canakinumab may cause a... |
DB08899 | DB09039 | 129 | 1,670 | [
"DDInter649",
"DDInter629"
] | Enzalutamide | Eliglustat | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Major | 2 | [
[
[
129,
25,
1670
]
],
[
[
129,
63,
479
],
[
479,
23,
1670
]
],
[
[
129,
25,
1135
],
[
1135,
62,
1670
]
],
[
[
129,
64,
1409
],
[
1409,
... | [
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepez... | Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Enzalutamide may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a ... |
DB06441 | DB06754 | 936 | 707 | [
"DDInter283",
"DDInter471"
] | Cangrelor | Danaparoid | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an act... | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity t... | Major | 2 | [
[
[
936,
25,
707
]
],
[
[
936,
23,
944
],
[
944,
62,
707
]
],
[
[
936,
24,
1496
],
[
1496,
63,
707
]
],
[
[
936,
63,
901
],
[
901,
2... | [
[
[
"Cangrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
]
],
[
[
"Cangrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Cangrelor may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Danaparoid
Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may... |
DB01004 | DB01168 | 563 | 1,053 | [
"DDInter806",
"DDInter1526"
] | Ganciclovir | Procarbazine | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
563,
24,
1053
]
],
[
[
563,
21,
28762
],
[
28762,
60,
1053
]
],
[
[
563,
63,
1648
],
[
1648,
24,
1053
]
],
[
[
563,
24,
738
],
[
738,
... | [
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Ganciclovir",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is ca... | Ganciclovir (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Procarbazine (Compound)
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Pro... |
DB00277 | DB00431 | 1,031 | 1,503 | [
"DDInter1791",
"DDInter1072"
] | Theophylline | Lindane | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due ... | Moderate | 1 | [
[
[
1031,
24,
1503
]
],
[
[
1031,
21,
28703
],
[
28703,
60,
1503
]
],
[
[
1031,
24,
1613
],
[
1613,
63,
1503
]
],
[
[
1031,
24,
62
],
[
62... | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lindane"
]
],
[
[
"Theophylline",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is cause... | Theophylline (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Lindane (Compound)
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases wh... |
DB00220 | DB09082 | 798 | 659 | [
"DDInter1276",
"DDInter1934"
] | Nelfinavir | Vilanterol | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
798,
24,
659
]
],
[
[
798,
24,
1220
],
[
1220,
23,
659
]
],
[
[
798,
63,
1351
],
[
1351,
23,
659
]
],
[
[
798,
25,
175
],
[
175,
... | [
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[... | Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Flunisolide and F... |
DB01362 | DB09333 | 497 | 278 | [
"DDInter960",
"DDInter963"
] | Iohexol | Iopodic acid | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Iopodic acid, also known by the name of ipodate, is classified as a cholecystographic agent formed by a weak organic acid that contains a tri-iodinated benzene ring with iodine at positions 2, 4 and 6. Due to its particular structure, it presents a high degree of lipid solubility and a radiopaque property. It was devel... | Moderate | 1 | [
[
[
497,
24,
278
]
],
[
[
497,
63,
461
],
[
461,
24,
278
]
],
[
[
497,
64,
1648
],
[
1648,
24,
278
]
],
[
[
497,
24,
116
],
[
116,
2... | [
[
[
"Iohexol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Iohexol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
"Ti... | Iohexol may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Iohexol may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a modera... |
DB00211 | DB01001 | 1,290 | 688 | [
"DDInter1213",
"DDInter1632"
] | Midodrine | Salbutamol | An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension. | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Moderate | 1 | [
[
[
1290,
24,
688
]
],
[
[
1290,
24,
874
],
[
874,
24,
688
]
],
[
[
1290,
21,
28714
],
[
28714,
60,
688
]
],
[
[
1290,
24,
870
],
[
870,
... | [
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
... | Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Midodrine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Salbutamol (Compound... |
DB00502 | DB01362 | 1,300 | 497 | [
"DDInter853",
"DDInter960"
] | Haloperidol | Iohexol | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
1300,
25,
497
]
],
[
[
1300,
21,
28681
],
[
28681,
60,
497
]
],
[
[
1300,
63,
999
],
[
999,
25,
497
]
],
[
[
1300,
25,
1264
],
[
1264,... | [
[
[
"Haloperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Haloperidol",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused... | Haloperidol (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may lead to a major life threatening interaction when taken wi... |
DB01263 | DB06595 | 859 | 1,491 | [
"DDInter1494",
"DDInter1214"
] | Posaconazole | Midostaurin | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Major | 2 | [
[
[
859,
25,
1491
]
],
[
[
859,
25,
1135
],
[
1135,
62,
1491
]
],
[
[
859,
62,
112
],
[
112,
23,
1491
]
],
[
[
859,
24,
761
],
[
761,
... | [
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u... | Posaconazole may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Posaconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may c... |
DB00231 | DB00514 | 1,174 | 506 | [
"DDInter1761",
"DDInter527"
] | Temazepam | Dextromethorphan | Temazepam, like many other similar and related benzodiazepines, acts as a gamma-aminobutyric acid (GABA) modulator and is capable of eliciting a variety of actions including sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, and anxiolytic action [A175207, A175210, F3718, F3721]. Although the chem... | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Moderate | 1 | [
[
[
1174,
24,
506
]
],
[
[
1174,
6,
8374
],
[
8374,
45,
506
]
],
[
[
1174,
21,
28750
],
[
28750,
60,
506
]
],
[
[
1174,
1,
902
],
[
902,
... | [
[
[
"Temazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
]
],
[
[
"Temazepam",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Temazepam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dextromethorphan (Compound)
Temazepam (Compound) causes Abdominal discomfort (Side Effect) and Abdominal discomfort (Side Effect) is caused by Dextromethorphan (Compound)
Temazepam (Compound) resembles Clobazam (Compound) and Clobazam may cause a mo... |
DB09293 | DB12834 | 116 | 148 | [
"DDInter954",
"DDInter1649"
] | Iodide I-131 | Secnidazole | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation do... | Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive ... | Moderate | 1 | [
[
[
116,
24,
148
]
],
[
[
116,
24,
1434
],
[
1434,
24,
148
]
],
[
[
116,
63,
458
],
[
458,
24,
148
]
],
[
[
116,
64,
33
],
[
33,
24,... | [
[
[
"Iodide I-131",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
]
],
[
[
"Iodide I-131",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
],
... | Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole and Benznidazole may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Tinidazole a... |
DB06081 | DB06700 | 1,046 | 643 | [
"DDInter286",
"DDInter511"
] | Caplacizumab | Desvenlafaxine | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of ad... | Moderate | 1 | [
[
[
1046,
24,
643
]
],
[
[
1046,
63,
1100
],
[
1100,
1,
643
]
],
[
[
1046,
25,
292
],
[
292,
63,
643
]
],
[
[
1046,
63,
1274
],
[
1274,
... | [
[
[
"Caplacizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Caplacizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],... | Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine (Compound) resembles Desvenlafaxine (Compound)
Caplacizumab may lead to a major life threatening interaction when taken with Regorafenib and Regorafenib may cause a moderate interaction that could ex... |
DB00204 | DB00816 | 228 | 1,674 | [
"DDInter580",
"DDInter1346"
] | Dofetilide | Orciprenaline | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Major | 2 | [
[
[
228,
25,
1674
]
],
[
[
228,
21,
28921
],
[
28921,
60,
1674
]
],
[
[
228,
23,
891
],
[
891,
62,
1674
]
],
[
[
228,
25,
167
],
[
167,
... | [
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Orciprenaline"
]
],
[
[
"Dofetilide",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (C... | Dofetilide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Orciprenaline (Compound)
Dofetilide may cause a minor interaction that can limit clinical effects when taken with Prednisolone and Prednisolone may cause a minor interaction that can limit clinical effects when taken with Orci... |
DB00372 | DB00747 | 999 | 1,442 | [
"DDInter1793",
"DDInter1647"
] | Thiethylperazine | Scopolamine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Moderate | 1 | [
[
[
999,
24,
1442
]
],
[
[
999,
24,
19
],
[
19,
24,
1442
]
],
[
[
999,
63,
1089
],
[
1089,
24,
1442
]
],
[
[
999,
24,
811
],
[
811,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Scopolamine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Ipratr... |
DB12267 | DB13074 | 1,476 | 877 | [
"DDInter233",
"DDInter1110"
] | Brigatinib | Macimorelin | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Moderate | 1 | [
[
[
1476,
24,
877
]
],
[
[
1476,
63,
1320
],
[
1320,
24,
877
]
],
[
[
1476,
64,
651
],
[
651,
24,
877
]
],
[
[
1476,
24,
1654
],
[
1654,
... | [
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
... | Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Brigatinib may lead to a major life threatening interaction when taken with Fosphenytoin and Fosphenytoin may cause... |
DB00748 | DB01178 | 662 | 369 | [
"DDInter297",
"DDInter357"
] | Carbinoxamine | Chlormezanone | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm. | Moderate | 1 | [
[
[
662,
24,
369
]
],
[
[
662,
24,
1532
],
[
1532,
63,
369
]
],
[
[
662,
35,
272
],
[
272,
24,
369
]
],
[
[
662,
63,
13
],
[
13,
24,... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlormezanone"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],... | Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Chlormezanone
Carbinoxamine (Compound) resembles Chlorpheniramine (Compound) and Carbinoxamine may cause a moderate inte... |
DB00581 | DB11113 | 355 | 657 | [
"DDInter1018",
"DDInter307"
] | Lactulose | Castor oil | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
355,
24,
657
]
],
[
[
355,
23,
16
],
[
16,
23,
657
]
],
[
[
355,
24,
1079
],
[
1079,
24,
657
]
],
[
[
355,
24,
927
],
[
927,
63,... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Lactulose",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Linaclotide"
],
[
... | Lactulose may cause a minor interaction that can limit clinical effects when taken with Linaclotide and Linaclotide may cause a minor interaction that can limit clinical effects when taken with Castor oil
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin... |
DB00758 | DB01076 | 1,347 | 700 | [
"DDInter413",
"DDInter133"
] | Clopidogrel | Atorvastatin | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Moderate | 1 | [
[
[
1347,
24,
700
]
],
[
[
1347,
23,
671
],
[
671,
1,
700
]
],
[
[
1347,
5,
11576
],
[
11576,
44,
700
]
],
[
[
1347,
6,
4973
],
[
4973,
... | [
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
],
[
[
"Clopidogrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluvastatin"
],
[... | Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Fluvastatin and Fluvastatin (Compound) resembles Atorvastatin (Compound)
Clopidogrel (Compound) treats coronary artery disease (Disease) and coronary artery disease (Disease) is treated by Atorvastatin (Compound)
Clopidogrel (Comp... |
DB01191 | DB06292 | 1,039 | 549 | [
"DDInter518",
"DDInter474"
] | Dexfenfluramine | Dapagliflozin | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
1039,
24,
549
]
],
[
[
1039,
24,
1344
],
[
1344,
40,
549
]
],
[
[
1039,
6,
8717
],
[
8717,
45,
549
]
],
[
[
1039,
24,
292
],
[
292,
... | [
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"... | Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Dexfenfluramine (Compound) binds CYP2A6 (Gene) and CYP2A6 (Gene) is bound by Dapagliflozin (Compound)
Dexfenfluramine may cause a moderate interac... |
DB01181 | DB01563 | 1,532 | 680 | [
"DDInter906",
"DDInter349"
] | Ifosfamide | Chloral hydrate | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | A hypnotic and sedative used in the treatment of insomnia. The safety margin is too narrow for chloral hydrate to be used as a general anesthetic in humans, but it is commonly used for that purpose in animal experiments. It is no longer considered useful as an anti-anxiety medication. | Moderate | 1 | [
[
[
1532,
24,
680
]
],
[
[
1532,
63,
272
],
[
272,
24,
680
]
],
[
[
1532,
24,
1311
],
[
1311,
24,
680
]
],
[
[
1532,
24,
516
],
[
516,
... | [
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloral hydrate"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
... | Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Chloral hydrate
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Meto... |
DB00515 | DB08880 | 589 | 1,510 | [
"DDInter387",
"DDInter1771"
] | Cisplatin | Teriflunomide | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
589,
25,
1510
]
],
[
[
589,
63,
1461
],
[
1461,
23,
1510
]
],
[
[
589,
24,
221
],
[
221,
63,
1510
]
],
[
[
589,
24,
1136
],
[
1136,
... | [
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E"... | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antige... |
DB06643 | DB11834 | 1,136 | 1,303 | [
"DDInter500",
"DDInter849"
] | Denosumab | Guselkumab | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstra... | Moderate | 1 | [
[
[
1136,
24,
1303
]
],
[
[
1136,
24,
713
],
[
713,
24,
1303
]
],
[
[
1136,
63,
58
],
[
58,
24,
1303
]
],
[
[
1136,
24,
270
],
[
270,
... | [
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
... | Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept... |
DB00783 | DB01011 | 1,438 | 925 | [
"DDInter680",
"DDInter1204"
] | Estradiol (topical) | Metyrapone | 17beta-estradiol is the 17beta-isomer of estradiol. It has a role as an estrogen, a human metabolite, an EC 1.2.3.1 (aldehyde oxidase) inhibitor, a Daphnia magna metabolite, a mouse metabolite and a geroprotector. It is a 17beta-hydroxy steroid and an estradiol. | An inhibitor of the enzyme steroid 11-beta-monooxygenase. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome. | Moderate | 1 | [
[
[
1438,
24,
925
]
],
[
[
1438,
6,
8374
],
[
8374,
45,
925
]
],
[
[
1438,
18,
10239
],
[
10239,
57,
925
]
],
[
[
1438,
21,
28810
],
[
288... | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metyrapone"
]
],
[
[
"Estradiol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Metyrapone
Estradiol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Metyrapone (Compound)
Estradiol (Compound) downregulates PMM2 (Gene) and PMM2 (Gene) is downregulated by Metyrapone (Compound)
Estradiol (Compound) ... |
DB05812 | DB06595 | 1,374 | 1,491 | [
"DDInter8",
"DDInter1214"
] | Abiraterone | Midostaurin | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
1374,
24,
1491
]
],
[
[
1374,
23,
1135
],
[
1135,
62,
1491
]
],
[
[
1374,
62,
112
],
[
112,
23,
1491
]
],
[
[
1374,
64,
888
],
[
888,
... | [
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Abiraterone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Abiraterone may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Abiraterone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronid... |
DB05294 | DB09083 | 1,069 | 880 | [
"DDInter1917",
"DDInter996"
] | Vandetanib | Ivabradine | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Major | 2 | [
[
[
1069,
25,
880
]
],
[
[
1069,
63,
480
],
[
480,
24,
880
]
],
[
[
1069,
24,
159
],
[
159,
63,
880
]
],
[
[
1069,
24,
1040
],
[
1040,
... | [
[
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Vandetanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol... | Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Lar... |
DB00501 | DB06414 | 752 | 655 | [
"DDInter380",
"DDInter703"
] | Cimetidine | Etravirine | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 10... | Moderate | 1 | [
[
[
752,
24,
655
]
],
[
[
752,
25,
786
],
[
786,
40,
655
]
],
[
[
752,
6,
4973
],
[
4973,
45,
655
]
],
[
[
752,
21,
28680
],
[
28680,
... | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
]
],
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilpivirine"
],
[
"Rilpiviri... | Cimetidine may lead to a major life threatening interaction when taken with Rilpivirine and Rilpivirine (Compound) resembles Etravirine (Compound)
Cimetidine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Etravirine (Compound)
Cimetidine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused ... |
DB00986 | DB01400 | 1,192 | 1,372 | [
"DDInter834",
"DDInter1279"
] | Glycopyrronium | Neostigmine | Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its ... | A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. | Moderate | 1 | [
[
[
1192,
24,
1372
]
],
[
[
1192,
63,
751
],
[
751,
40,
1372
]
],
[
[
1192,
24,
61
],
[
61,
24,
1372
]
],
[
[
1192,
21,
28705
],
[
28705,
... | [
[
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
]
],
[
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pyridostigmine"
... | Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Pyridostigmine and Pyridostigmine (Compound) resembles Neostigmine (Compound)
Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium and Edrophonium may cause a moderate int... |
DB00719 | DB11823 | 1,219 | 858 | [
"DDInter149",
"DDInter673"
] | Azatadine | Esketamine | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide.[L5596,A175462] On March 5, 2019, the nasal spray drug, _esketamine_, also known as _Spravato_ (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression. Eske... | Moderate | 1 | [
[
[
1219,
24,
858
]
],
[
[
1219,
24,
272
],
[
272,
24,
858
]
],
[
[
1219,
63,
506
],
[
506,
24,
858
]
],
[
[
1219,
40,
830
],
[
830,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Dextrometho... |
DB00637 | DB00744 | 1,557 | 1,288 | [
"DDInter128",
"DDInter1962"
] | Astemizole | Zileuton | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, a... | Moderate | 1 | [
[
[
1557,
24,
1288
]
],
[
[
1557,
6,
8374
],
[
8374,
45,
1288
]
],
[
[
1557,
24,
1297
],
[
1297,
63,
1288
]
],
[
[
1557,
25,
868
],
[
868,... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zileuton"
]
],
[
[
"Astemizole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Astemizole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Zileuton (Compound)
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Zileuton
Astemizole may lea... |
DB01017 | DB09564 | 1,669 | 1,296 | [
"DDInter1224",
"DDInter930"
] | Minocycline | Insulin degludec | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
1669,
24,
1296
]
],
[
[
1669,
23,
674
],
[
674,
24,
1296
]
],
[
[
1669,
62,
811
],
[
811,
24,
1296
]
],
[
[
1669,
40,
964
],
[
964,
... | [
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Minocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trichlormethiazide"
... | Minocycline may cause a minor interaction that can limit clinical effects when taken with Trichlormethiazide and Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Minocycline may cause a minor interaction that can limit clinical effects when taken with M... |
DB00615 | DB08881 | 690 | 868 | [
"DDInter1589",
"DDInter1925"
] | Rifabutin | Vemurafenib | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
690,
25,
868
]
],
[
[
690,
6,
8374
],
[
8374,
45,
868
]
],
[
[
690,
7,
3727
],
[
3727,
46,
868
]
],
[
[
690,
18,
2183
],
[
2183,
... | [
[
[
"Rifabutin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Rifabutin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vemurafe... | Rifabutin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Rifabutin (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Vemurafenib (Compound)
Rifabutin (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Vemurafenib (Compound)
Rifabutin (Compoun... |
DB00451 | DB00621 | 542 | 1,026 | [
"DDInter1064",
"DDInter1357"
] | Levothyroxine | Oxandrolone | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quant... | A synthetic hormone with anabolic and androgenic properties. | Moderate | 1 | [
[
[
542,
24,
1026
]
],
[
[
542,
24,
1546
],
[
1546,
1,
1026
]
],
[
[
542,
21,
28905
],
[
28905,
60,
1026
]
],
[
[
542,
24,
473
],
[
473,
... | [
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxandrolone"
]
],
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyltestosterone"
... | Levothyroxine may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Oxandrolone (Compound)
Levothyroxine (Compound) causes Irritability (Side Effect) and Irritability (Side Effect) is caused by Oxandrolone (Compound)
Levothyroxine ... |
DB00086 | DB08896 | 1,167 | 292 | [
"DDInter1712",
"DDInter1576"
] | Streptokinase | Regorafenib | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Major | 2 | [
[
[
1167,
25,
292
]
],
[
[
1167,
24,
643
],
[
643,
24,
292
]
],
[
[
1167,
24,
41
],
[
41,
63,
292
]
],
[
[
1167,
25,
553
],
[
553,
2... | [
[
[
"Streptokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
],
[
... | Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Levomi... |
DB01319 | DB09143 | 34 | 313 | [
"DDInter777",
"DDInter1701"
] | Fosamprenavir | Sonidegib | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Major | 2 | [
[
[
34,
25,
313
]
],
[
[
34,
63,
1194
],
[
1194,
23,
313
]
],
[
[
34,
24,
101
],
[
101,
23,
313
]
],
[
[
34,
25,
478
],
[
478,
24,
... | [
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ranitidine"
],
[
"Ranit... | Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole an... |
DB01197 | DB01234 | 1,603 | 1,220 | [
"DDInter292",
"DDInter513"
] | Captopril | Dexamethasone | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment ... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
1603,
24,
1220
]
],
[
[
1603,
63,
870
],
[
870,
1,
1220
]
],
[
[
1603,
63,
175
],
[
175,
40,
1220
]
],
[
[
1603,
24,
617
],
[
617,
... | [
[
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
... | Captopril may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Captopril may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexam... |
DB06603 | DB11988 | 39 | 270 | [
"DDInter1387",
"DDInter1321"
] | Panobinostat | Ocrelizumab | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
39,
24,
270
]
],
[
[
39,
64,
1491
],
[
1491,
24,
270
]
],
[
[
39,
24,
951
],
[
951,
24,
270
]
],
[
[
39,
63,
259
],
[
259,
24,
... | [
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
],
[
"Mido... | Panobinostat may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib m... |
DB01208 | DB08868 | 945 | 1,011 | [
"DDInter1705",
"DDInter737"
] | Sparfloxacin | Fingolimod | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
945,
25,
1011
]
],
[
[
945,
21,
29097
],
[
29097,
60,
1011
]
],
[
[
945,
62,
112
],
[
112,
23,
1011
]
],
[
[
945,
24,
144
],
[
144,
... | [
[
[
"Sparfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Sparfloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Eye pain"
],
[
"Eye pain",
"{u} (Side Effect) is caused by {v} (Co... | Sparfloxacin (Compound) causes Eye pain (Side Effect) and Eye pain (Side Effect) is caused by Fingolimod (Compound)
Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Fin... |
DB00432 | DB04865 | 1,083 | 4 | [
"DDInter1868",
"DDInter1335"
] | Trifluridine | Omacetaxine mepesuccinate | Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine]. It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. It displays effective antiviral activity... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
1083,
24,
4
]
],
[
[
1083,
7,
7806
],
[
7806,
46,
4
]
],
[
[
1083,
6,
8569
],
[
8569,
57,
4
]
],
[
[
1083,
18,
18560
],
[
18560,
... | [
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Trifluridine",
"{u} (Compound) upregulates {v} (Gene)",
"INPP1"
],
[
"INPP1",
"{u} (Gene) is up... | Trifluridine (Compound) upregulates INPP1 (Gene) and INPP1 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Trifluridine (Compound) binds TYMS (Gene) and TYMS (Gene) is downregulated by Omacetaxine mepesuccinate (Compound)
Trifluridine (Compound) downregulates PSRC1 (Gene) and PSRC1 (Gene) is downregulated... |
DB00060 | DB12500 | 912 | 283 | [
"DDInter947",
"DDInter714"
] | Interferon beta-1a | Fedratinib | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
912,
24,
283
]
],
[
[
912,
24,
351
],
[
351,
23,
283
]
],
[
[
912,
24,
69
],
[
69,
63,
283
]
],
[
[
912,
24,
1398
],
[
1398,
24,... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Pralset... |
DB00316 | DB01233 | 474 | 1,311 | [
"DDInter14",
"DDInter1197"
] | Acetaminophen | Metoclopramide | Acetaminophen (paracetamol), also commonly known as _Tylenol_, is the most commonly taken analgesic worldwide and is recommended as first-line therapy in pain conditions by the World Health Organization (WHO). It is also used for its antipyretic effects, helping to reduce fever. This drug was initially approved by the ... | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Minor | 0 | [
[
[
474,
23,
1311
]
],
[
[
474,
6,
12523
],
[
12523,
45,
1311
]
],
[
[
474,
10,
11610
],
[
11610,
49,
1311
]
],
[
[
474,
21,
28691
],
[
28... | [
[
[
"Acetaminophen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metoclopramide"
]
],
[
[
"Acetaminophen",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Com... | Acetaminophen (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Metoclopramide (Compound)
Acetaminophen (Compound) palliates migraine (Disease) and migraine (Disease) is palliated by Metoclopramide (Compound)
Acetaminophen (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by M... |
DB01082 | DB01172 | 1,448 | 416 | [
"DDInter1713",
"DDInter1004"
] | Streptomycin | Kanamycin | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Moderate | 1 | [
[
[
1448,
35,
416
]
],
[
[
1448,
1,
437
],
[
437,
40,
416
]
],
[
[
1448,
54,
19175
],
[
19175,
15,
416
]
],
[
[
1448,
21,
31264
],
[
31264... | [
[
[
"Streptomycin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Streptomycin",
"{u} (Compound) resembles {v} (Compound)",
"Amikacin"
],
[
... | Streptomycin (Compound) resembles Kanamycin (Compound) and
Streptomycin (Compound) resembles Amikacin (Compound) and Amikacin (Compound) resembles Kanamycin (Compound)
Streptomycin (Compound) is included by Aminoglycosides (Pharmacologic Class) and Aminoglycosides (Pharmacologic Class) includes Kanamycin (Compound)
Str... |
DB11767 | DB14730 | 1,583 | 1,412 | [
"DDInter1643",
"DDInter264"
] | Sarilumab | Calaspargase pegol | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approve... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
1583,
24,
1412
]
],
[
[
1583,
63,
792
],
[
792,
24,
1412
]
],
[
[
1583,
64,
581
],
[
581,
24,
1412
]
],
[
[
1583,
64,
1377
],
[
1377,
... | [
[
[
"Sarilumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Sarilumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
],
... | Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Sarilumab may lead to a major life threatening interaction when taken with Infliximab and Infliximab ma... |
DB00188 | DB00704 | 168 | 267 | [
"DDInter222",
"DDInter1263"
] | Bortezomib | Naltrexone | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | Moderate | 1 | [
[
[
168,
24,
267
]
],
[
[
168,
7,
3163
],
[
3163,
46,
267
]
],
[
[
168,
7,
20113
],
[
20113,
57,
267
]
],
[
[
168,
18,
6168
],
[
6168,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
]
],
[
[
"Bortezomib",
"{u} (Compound) upregulates {v} (Gene)",
"TSC22D3"
],
[
"TSC22D3",
"{u} (Gene) is upregulated by {v... | Bortezomib (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Naltrexone (Compound)
Bortezomib (Compound) upregulates IER3 (Gene) and IER3 (Gene) is downregulated by Naltrexone (Compound)
Bortezomib (Compound) downregulates IGFBP3 (Gene) and IGFBP3 (Gene) is downregulated by Naltrexone (Compound... |
DB00277 | DB01193 | 1,031 | 819 | [
"DDInter1791",
"DDInter12"
] | Theophylline | Acebutolol | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Major | 2 | [
[
[
1031,
25,
819
]
],
[
[
1031,
25,
887
],
[
887,
1,
819
]
],
[
[
1031,
64,
726
],
[
726,
1,
819
]
],
[
[
1031,
6,
12523
],
[
12523,
... | [
[
[
"Theophylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acebutolol"
]
],
[
[
"Theophylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pindolol"
],
[
"Pindolol",
"{u} (... | Theophylline may lead to a major life threatening interaction when taken with Pindolol and Pindolol (Compound) resembles Acebutolol (Compound)
Theophylline may lead to a major life threatening interaction when taken with Betaxolol and Betaxolol (Compound) resembles Acebutolol (Compound)
Theophylline (Compound) binds CY... |
DB00186 | DB09481 | 905 | 460 | [
"DDInter1092",
"DDInter1113"
] | Lorazepam | Magnesium carbonate | Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm. | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Minor | 0 | [
[
[
905,
23,
460
]
],
[
[
905,
24,
401
],
[
401,
23,
460
]
],
[
[
905,
40,
1382
],
[
1382,
23,
460
]
],
[
[
905,
23,
1283
],
[
1283,
... | [
[
[
"Lorazepam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Lorazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
... | Lorazepam may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Lorazepam (Compound) resembles Midazolam (Compound) and Midazolam may cause a minor interaction that c... |
DB00242 | DB00791 | 1,064 | 132 | [
"DDInter392",
"DDInter1902"
] | Cladribine | Uracil mustard | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Nitrogen mustard derivative of uracil. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage. | Major | 2 | [
[
[
1064,
25,
132
]
],
[
[
1064,
25,
970
],
[
970,
40,
132
]
],
[
[
1064,
25,
1430
],
[
1430,
63,
132
]
],
[
[
1064,
24,
748
],
[
748,
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Uracil mustard"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluorouracil"
],
[
"Fluorouracil",
... | Cladribine may lead to a major life threatening interaction when taken with Fluorouracil and Fluorouracil (Compound) resembles Uracil mustard (Compound)
Cladribine may lead to a major life threatening interaction when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseas... |
DB00465 | DB08880 | 886 | 1,510 | [
"DDInter1010",
"DDInter1771"
] | Ketorolac | Teriflunomide | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
886,
25,
1510
]
],
[
[
886,
24,
1144
],
[
1144,
24,
1510
]
],
[
[
886,
63,
1061
],
[
1061,
24,
1510
]
],
[
[
886,
23,
752
],
[
752,
... | [
[
[
"Ketorolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglin... | Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and T... |
DB00570 | DB09498 | 147 | 810 | [
"DDInter1936",
"DDInter1715"
] | Vinblastine | Strontium chloride Sr-89 | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Moderate | 1 | [
[
[
147,
24,
810
]
],
[
[
147,
63,
552
],
[
552,
24,
810
]
],
[
[
147,
23,
60
],
[
60,
24,
810
]
],
[
[
147,
24,
1224
],
[
1224,
24,... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Vinblastine may cause a minor interaction that can limit clinical effects when taken with Capecit... |
DB00014 | DB04868 | 521 | 478 | [
"DDInter839",
"DDInter1293"
] | Goserelin | Nilotinib | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
521,
25,
478
]
],
[
[
521,
21,
28963
],
[
28963,
60,
478
]
],
[
[
521,
23,
1247
],
[
1247,
23,
478
]
],
[
[
521,
24,
479
],
[
479,
... | [
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Goserelin",
"{u} (Compound) causes {v} (Side Effect)",
"Anxiety"
],
[
"Anxiety",
"{u} (Side Effect) is caused by {v} (Compound)",... | Goserelin (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Nilotinib (Compound)
Goserelin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Niloti... |
DB09046 | DB11952 | 1,094 | 800 | [
"DDInter1201",
"DDInter612"
] | Metreleptin | Duvelisib | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Moderate | 1 | [
[
[
1094,
24,
800
]
],
[
[
1094,
24,
466
],
[
466,
62,
800
]
],
[
[
1094,
24,
1476
],
[
1476,
63,
800
]
],
[
[
1094,
63,
254
],
[
254,
... | [
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[... | Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Duvelisib
Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Bri... |
DB00604 | DB08868 | 1,425 | 1,011 | [
"DDInter385",
"DDInter737"
] | Cisapride | Fingolimod | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
1425,
25,
1011
]
],
[
[
1425,
6,
12523
],
[
12523,
45,
1011
]
],
[
[
1425,
23,
1247
],
[
1247,
23,
1011
]
],
[
[
1425,
24,
578
],
[
57... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Cisapride",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Fingolimo... | Cisapride (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fingolimod (Compound)
Cisapride may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Fingolimod
Cisapride ma... |
DB00612 | DB09333 | 1,121 | 278 | [
"DDInter216",
"DDInter963"
] | Bisoprolol | Iopodic acid | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-ad... | Iopodic acid, also known by the name of ipodate, is classified as a cholecystographic agent formed by a weak organic acid that contains a tri-iodinated benzene ring with iodine at positions 2, 4 and 6. Due to its particular structure, it presents a high degree of lipid solubility and a radiopaque property. It was devel... | Moderate | 1 | [
[
[
1121,
24,
278
]
],
[
[
1121,
63,
1648
],
[
1648,
24,
278
]
],
[
[
1121,
24,
1527
],
[
1527,
24,
278
]
],
[
[
1121,
40,
726
],
[
726,
... | [
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[... | Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid a... |
DB01088 | DB04948 | 714 | 1,084 | [
"DDInter908",
"DDInter1083"
] | Iloprost | Lofexidine | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Moderate | 1 | [
[
[
714,
24,
1084
]
],
[
[
714,
63,
1617
],
[
1617,
1,
1084
]
],
[
[
714,
24,
222
],
[
222,
24,
1084
]
],
[
[
714,
24,
1450
],
[
1450,
... | [
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apraclonidine"
],
[
... | Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Apraclonidine and Apraclonidine (Compound) resembles Lofexidine (Compound)
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that c... |
DB08882 | DB08912 | 1,281 | 1,040 | [
"DDInter1070",
"DDInter462"
] | Linagliptin | Dabrafenib | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin w... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
1281,
24,
1040
]
],
[
[
1281,
6,
4973
],
[
4973,
45,
1040
]
],
[
[
1281,
21,
28787
],
[
28787,
60,
1040
]
],
[
[
1281,
63,
168
],
[
16... | [
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Linagliptin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",... | Linagliptin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Linagliptin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Dabrafenib (Compound)
Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and B... |
DB00650 | DB00832 | 1,147 | 499 | [
"DDInter1041",
"DDInter1446"
] | Leucovorin | Phensuximide | Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharma... | Phensuximide is a member of the succinimide class with anticonvulsant properties. It suppresses the paroxysmal three cycle per second spike and wave EEG pattern associated with lapses of consciousness in petit mal seizures. The frequency of attacks is reduced by depression of nerve transmission in the motor cortex. | Moderate | 1 | [
[
[
1147,
24,
499
]
],
[
[
1147,
24,
157
],
[
157,
40,
499
]
],
[
[
1147,
40,
356
],
[
356,
24,
499
]
],
[
[
1147,
24,
157
],
[
157,
... | [
[
[
"Leucovorin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phensuximide"
]
],
[
[
"Leucovorin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
],
[
... | Leucovorin may cause a moderate interaction that could exacerbate diseases when taken with Ethotoin and Ethotoin (Compound) resembles Phensuximide (Compound)
Leucovorin (Compound) resembles Folic acid (Compound) and Folic acid may cause a moderate interaction that could exacerbate diseases when taken with Phensuximide
... |
DB00490 | DB01233 | 946 | 1,311 | [
"DDInter254",
"DDInter1197"
] | Buspirone | Metoclopramide | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic dr... | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
946,
24,
1311
]
],
[
[
946,
6,
5289
],
[
5289,
45,
1311
]
],
[
[
946,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
946,
24,
629
],
[
629,
... | [
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Buspirone",
"{u} (Compound) binds {v} (Gene)",
"DRD3"
],
[
"DRD3",
"{u} (Gene) is bound by {v} (Compound)",
... | Buspirone (Compound) binds DRD3 (Gene) and DRD3 (Gene) is bound by Metoclopramide (Compound)
Buspirone (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Si... |
DB00831 | DB01169 | 1,178 | 57 | [
"DDInter1866",
"DDInter120"
] | Trifluoperazine | Arsenic trioxide | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Major | 2 | [
[
[
1178,
25,
57
]
],
[
[
1178,
6,
4973
],
[
4973,
45,
57
]
],
[
[
1178,
23,
112
],
[
112,
23,
57
]
],
[
[
1178,
24,
603
],
[
603,
6... | [
[
[
"Trifluoperazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Trifluoperazine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Trifluoperazine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Arsenic trioxide (Compound)
Trifluoperazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Arsenic triox... |
DB00476 | DB01088 | 109 | 714 | [
"DDInter608",
"DDInter908"
] | Duloxetine | Iloprost | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
109,
24,
714
]
],
[
[
109,
24,
1479
],
[
1479,
24,
714
]
],
[
[
109,
63,
1648
],
[
1648,
24,
714
]
],
[
[
109,
40,
758
],
[
758,
... | [
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
... | Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Ald... |
DB08827 | DB09078 | 990 | 1,228 | [
"DDInter1085",
"DDInter1036"
] | Lomitapide | Lenvatinib | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Major | 2 | [
[
[
990,
25,
1228
]
],
[
[
990,
64,
609
],
[
609,
24,
1228
]
],
[
[
990,
63,
77
],
[
77,
24,
1228
]
],
[
[
990,
25,
384
],
[
384,
24... | [
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
... | Lomitapide may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin ma... |
DB06674 | DB09052 | 908 | 250 | [
"DDInter837",
"DDInter220"
] | Golimumab | Blinatumomab | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Major | 2 | [
[
[
908,
25,
250
]
],
[
[
908,
24,
949
],
[
949,
63,
250
]
],
[
[
908,
25,
1362
],
[
1362,
63,
250
]
],
[
[
908,
64,
305
],
[
305,
2... | [
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Blinatumomab"
]
],
[
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formald... | Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Golimumab m... |
DB00532 | DB01105 | 208 | 222 | [
"DDInter1152",
"DDInter1665"
] | Mephenytoin | Sibutramine | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
208,
24,
222
]
],
[
[
208,
24,
384
],
[
384,
62,
222
]
],
[
[
208,
64,
600
],
[
600,
23,
222
]
],
[
[
208,
63,
128
],
[
128,
24,... | [
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[... | Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Mephenytoin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cau... |
DB01381 | DB06081 | 958 | 1,046 | [
"DDInter819",
"DDInter286"
] | Ginkgo biloba | Caplacizumab | _Ginkgo biloba_ extract contains a group of terpene lactones (notably, ginkgolides and diterpenes) and ginkgo flavone glycosides (notably, ginkgetin, bilobetin, and sciadopitysin) that have antioxidant and vasoactive properties. Most of the studies that investigate the effect of _ginkgo biloba_ use the standardized ext... | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Moderate | 1 | [
[
[
958,
24,
1046
]
],
[
[
958,
63,
1039
],
[
1039,
24,
1046
]
],
[
[
958,
63,
1479
],
[
1479,
25,
1046
]
],
[
[
958,
24,
256
],
[
256,
... | [
[
[
"Ginkgo biloba",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Caplacizumab"
]
],
[
[
"Ginkgo biloba",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
... | Ginkgo biloba may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab
Ginkgo biloba may cause a moderate interaction that could exacerbate diseases when taken with Ace... |
DB06448 | DB09079 | 171 | 1,496 | [
"DDInter1087",
"DDInter1296"
] | Lonafarnib | Nintedanib | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis trea... | Moderate | 1 | [
[
[
171,
24,
1496
]
],
[
[
171,
64,
609
],
[
609,
24,
1496
]
],
[
[
171,
25,
840
],
[
840,
24,
1496
]
],
[
[
171,
25,
913
],
[
913,
... | [
[
[
"Lonafarnib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarit... | Lonafarnib may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Lonafarnib may lead to a major life threatening interaction when taken with Vorapaxar and Vorapaxar may cause a moderat... |
DB00420 | DB09082 | 508 | 659 | [
"DDInter1532",
"DDInter1934"
] | Promazine | Vilanterol | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
508,
24,
659
]
],
[
[
508,
24,
870
],
[
870,
23,
659
]
],
[
[
508,
24,
1296
],
[
1296,
63,
659
]
],
[
[
508,
25,
1069
],
[
1069,
... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[... | Promazine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin deglude... |
DB08875 | DB11901 | 1,618 | 913 | [
"DDInter262",
"DDInter107"
] | Cabozantinib | Apalutamide | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
1618,
25,
913
]
],
[
[
1618,
62,
112
],
[
112,
23,
913
]
],
[
[
1618,
64,
279
],
[
279,
24,
913
]
],
[
[
1618,
24,
28
],
[
28,
2... | [
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Cabozantinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Cabozantinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Cabozantinib may lead to a major life threatening interaction when taken with Anisindione and Anisindione m... |
DB00445 | DB06603 | 322 | 39 | [
"DDInter655",
"DDInter1387"
] | Epirubicin | Panobinostat | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
322,
25,
39
]
],
[
[
322,
23,
1247
],
[
1247,
23,
39
]
],
[
[
322,
24,
479
],
[
479,
23,
39
]
],
[
[
322,
63,
912
],
[
912,
24,
... | [
[
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Epirubicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulf... | Epirubicin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Donepezil a... |
DB00342 | DB12095 | 1,181 | 179 | [
"DDInter1770",
"DDInter1760"
] | Terfenadine | Telotristat ethyl | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Moderate | 1 | [
[
[
1181,
24,
179
]
],
[
[
1181,
24,
79
],
[
79,
24,
179
]
],
[
[
1181,
25,
1593
],
[
1593,
24,
179
]
],
[
[
1181,
24,
283
],
[
283,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Terfenadine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may... |
DB00757 | DB01149 | 1,166 | 851 | [
"DDInter581",
"DDInter1274"
] | Dolasetron | Nefazodone | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Major | 2 | [
[
[
1166,
25,
851
]
],
[
[
1166,
64,
252
],
[
252,
40,
851
]
],
[
[
1166,
25,
1178
],
[
1178,
1,
851
]
],
[
[
1166,
24,
673
],
[
673,
... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nefazodone"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u}... | Dolasetron may lead to a major life threatening interaction when taken with Hydroxyzine and Hydroxyzine (Compound) resembles Nefazodone (Compound)
Dolasetron may lead to a major life threatening interaction when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Nefazodone (Compound)
Dolasetron may cau... |
DB00562 | DB01067 | 1,014 | 959 | [
"DDInter188",
"DDInter826"
] | Benzthiazide | Glipizide | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
1014,
24,
959
]
],
[
[
1014,
63,
245
],
[
245,
40,
959
]
],
[
[
1014,
24,
1411
],
[
1411,
1,
959
]
],
[
[
1014,
24,
660
],
[
660,
... | [
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Comp... |
DB05679 | DB06273 | 1,683 | 980 | [
"DDInter1907",
"DDInter1824"
] | Ustekinumab | Tocilizumab | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Major | 2 | [
[
[
1683,
25,
980
]
],
[
[
1683,
23,
1114
],
[
1114,
62,
980
]
],
[
[
1683,
62,
1461
],
[
1461,
23,
980
]
],
[
[
1683,
63,
1428
],
[
1428,... | [
[
[
"Ustekinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tocilizumab"
]
],
[
[
"Ustekinumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc su... | Ustekinumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Tocilizumab
Ustekinumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitami... |
DB08826 | DB15762 | 1,292 | 725 | [
"DDInter489",
"DDInter1644"
] | Deferiprone | Satralizumab | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare au... | Major | 2 | [
[
[
1292,
25,
725
]
],
[
[
1292,
24,
1193
],
[
1193,
23,
725
]
],
[
[
1292,
25,
1362
],
[
1362,
24,
725
]
],
[
[
1292,
64,
372
],
[
372,
... | [
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Satralizumab"
]
],
[
[
"Deferiprone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate"
],
[
"Zi... | Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Satralizumab
Deferiprone may lead to a major life threatening interaction when taken with Olaparib and Olaparib may ... |
DB00531 | DB01156 | 450 | 593 | [
"DDInter456",
"DDInter252"
] | Cyclophosphamide | Bupropion | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Moderate | 1 | [
[
[
450,
24,
593
]
],
[
[
450,
6,
3486
],
[
3486,
45,
593
]
],
[
[
450,
18,
4930
],
[
4930,
57,
593
]
],
[
[
450,
21,
29087
],
[
29087,
... | [
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Cyclophosphamide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (... | Cyclophosphamide (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Bupropion (Compound)
Cyclophosphamide (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Bupropion (Compound)
Cyclophosphamide (Compound) causes Amenorrhoea (Side Effect) and Amenorrhoea (Side Effect) is caused by Bupropio... |
DB01142 | DB12130 | 1,264 | 1,017 | [
"DDInter593",
"DDInter1094"
] | Doxepin | Lorlatinib | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1264,
24,
1017
]
],
[
[
1264,
24,
1612
],
[
1612,
23,
1017
]
],
[
[
1264,
63,
590
],
[
590,
24,
1017
]
],
[
[
1264,
24,
786
],
[
786,
... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
"... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexa... |
DB00734 | DB01067 | 1,664 | 959 | [
"DDInter1605",
"DDInter826"
] | Risperidone | Glipizide | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
1664,
24,
959
]
],
[
[
1664,
63,
245
],
[
245,
40,
959
]
],
[
[
1664,
24,
1411
],
[
1411,
1,
959
]
],
[
[
1664,
6,
8374
],
[
8374,
... | [
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
... | Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compou... |
DB00196 | DB06603 | 600 | 39 | [
"DDInter743",
"DDInter1387"
] | Fluconazole | Panobinostat | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
600,
25,
39
]
],
[
[
600,
23,
1247
],
[
1247,
23,
39
]
],
[
[
600,
24,
211
],
[
211,
23,
39
]
],
[
[
600,
63,
912
],
[
912,
24,
... | [
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Su... | Fluconazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Tolterodi... |
DB00467 | DB01101 | 1,467 | 60 | [
"DDInter644",
"DDInter285"
] | Enoxacin | Capecitabine | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Minor | 0 | [
[
[
1467,
23,
60
]
],
[
[
1467,
1,
872
],
[
872,
62,
60
]
],
[
[
1467,
40,
1176
],
[
1176,
23,
60
]
],
[
[
1467,
24,
460
],
[
460,
6... | [
[
[
"Enoxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capecitabine"
]
],
[
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may cause a minor i... | Enoxacin (Compound) resembles Gemifloxacin (Compound) and Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Enoxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Capecitab... |
DB00352 | DB08932 | 482 | 1,398 | [
"DDInter1814",
"DDInter1111"
] | Tioguanine | Macitentan | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension. It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] due to its lower risk of hepatotoxicity. | Moderate | 1 | [
[
[
482,
24,
1398
]
],
[
[
482,
21,
29051
],
[
29051,
60,
1398
]
],
[
[
482,
24,
283
],
[
283,
63,
1398
]
],
[
[
482,
24,
1478
],
[
1478,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macitentan"
]
],
[
[
"Tioguanine",
"{u} (Compound) causes {v} (Side Effect)",
"Fluid retention"
],
[
"Fluid retention",
"{u} (Side Eff... | Tioguanine (Compound) causes Fluid retention (Side Effect) and Fluid retention (Side Effect) is caused by Macitentan (Compound)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken ... |
DB08901 | DB11601 | 1,468 | 1,270 | [
"DDInter1492",
"DDInter1889"
] | Ponatinib | Tuberculin purified protein derivative | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
1468,
24,
1270
]
],
[
[
1468,
63,
350
],
[
350,
24,
1270
]
],
[
[
1468,
64,
1064
],
[
1064,
24,
1270
]
],
[
[
1468,
24,
119
],
[
119,
... | [
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"C... | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Ponatinib may lead to a major life threatening interaction when taken with Cladribi... |
DB00902 | DB06016 | 104 | 1,508 | [
"DDInter1168",
"DDInter300"
] | Methdilazine | Cariprazine | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Moderate | 1 | [
[
[
104,
24,
1508
]
],
[
[
104,
24,
1637
],
[
1637,
24,
1508
]
],
[
[
104,
63,
1242
],
[
1242,
24,
1508
]
],
[
[
104,
24,
1450
],
[
1450,
... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
],
... | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite and Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine a... |
DB00388 | DB00938 | 1,636 | 455 | [
"DDInter1453",
"DDInter1635"
] | Phenylephrine | Salmeterol | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
1636,
24,
455
]
],
[
[
1636,
24,
1523
],
[
1523,
25,
455
]
],
[
[
1636,
24,
688
],
[
688,
63,
455
]
],
[
[
1636,
21,
29024
],
[
29024,... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],
... | Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol may lead to a major life threatening interaction when taken with Salmeterol
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may ca... |
DB00455 | DB08873 | 1,601 | 74 | [
"DDInter1091",
"DDInter221"
] | Loratadine | Boceprevir | Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis. A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations. | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in... | Moderate | 1 | [
[
[
1601,
24,
74
]
],
[
[
1601,
6,
4973
],
[
4973,
45,
74
]
],
[
[
1601,
21,
28769
],
[
28769,
60,
74
]
],
[
[
1601,
23,
86
],
[
86,
... | [
[
[
"Loratadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Loratadine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Loratadine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Boceprevir (Compound)
Loratadine (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Boceprevir (Compound)
Loratadine may cause a minor interaction that can limit clinical effects when taken with Miconazol... |
DB00290 | DB04865 | 329 | 4 | [
"DDInter219",
"DDInter1335"
] | Bleomycin | Omacetaxine mepesuccinate | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
329,
24,
4
]
],
[
[
329,
6,
7335
],
[
7335,
57,
4
]
],
[
[
329,
25,
770
],
[
770,
24,
4
]
],
[
[
329,
24,
496
],
[
496,
63,
... | [
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Bleomycin",
"{u} (Compound) binds {v} (Gene)",
"LIG1"
],
[
"LIG1",
"{u} (Gene) is downregulated by... | Bleomycin (Compound) binds LIG1 (Gene) and LIG1 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound)
Bleomycin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate... |
DB00798 | DB01226 | 1,132 | 1,319 | [
"DDInter815",
"DDInter1235"
] | Gentamicin | Mivacurium | Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negat... | Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. | Major | 2 | [
[
[
1132,
25,
1319
]
],
[
[
1132,
25,
648
],
[
648,
1,
1319
]
],
[
[
1132,
21,
28921
],
[
28921,
60,
1319
]
],
[
[
1132,
64,
1441
],
[
144... | [
[
[
"Gentamicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mivacurium"
]
],
[
[
"Gentamicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxacurium"
],
[
"Doxacurium",
"{u} (... | Gentamicin may lead to a major life threatening interaction when taken with Doxacurium and Doxacurium (Compound) resembles Mivacurium (Compound)
Gentamicin (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Mivacurium (Compound)
Gentamicin may lead to a major life threatening interaction... |
DB00731 | DB09068 | 1,144 | 1,427 | [
"DDInter1269",
"DDInter1948"
] | Nateglinide | Vortioxetine | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin r... | Moderate | 1 | [
[
[
1144,
24,
1427
]
],
[
[
1144,
24,
1017
],
[
1017,
63,
1427
]
],
[
[
1144,
24,
1220
],
[
1220,
24,
1427
]
],
[
[
1144,
63,
1512
],
[
15... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and... |
DB00317 | DB09065 | 883 | 760 | [
"DDInter810",
"DDInter424"
] | Gefitinib | Cobicistat | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
883,
24,
760
]
],
[
[
883,
23,
479
],
[
479,
23,
760
]
],
[
[
883,
24,
1627
],
[
1627,
23,
760
]
],
[
[
883,
63,
1101
],
[
1101,
... | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Gefitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"... | Gefitinib may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol m... |
DB01165 | DB06788 | 1,539 | 1,616 | [
"DDInter1325",
"DDInter864"
] | Ofloxacin | Histrelin | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Moderate | 1 | [
[
[
1539,
24,
1616
]
],
[
[
1539,
62,
112
],
[
112,
23,
1616
]
],
[
[
1539,
24,
1342
],
[
1342,
24,
1616
]
],
[
[
1539,
64,
1179
],
[
1179... | [
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Ofloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Ofloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidep... |
DB01226 | DB09407 | 1,319 | 853 | [
"DDInter1235",
"DDInter1114"
] | Mivacurium | Magnesium chloride | Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. | Magnesium chloride salts are highly soluble in water and the hydrated form of magnesium chloride can be extracted from brine or sea water. | Moderate | 1 | [
[
[
1319,
24,
853
]
],
[
[
1319,
63,
964
],
[
964,
24,
853
]
],
[
[
1319,
63,
964
],
[
964,
24,
544
],
[
544,
24,
853
]
],
[
[
1319,
... | [
[
[
"Mivacurium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
]
],
[
[
"Mivacurium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxycycline"
],... | Mivacurium may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride
Mivacurium may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.